Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Crit Rev Oncol Hematol. 2015 Jun;94(3):261-9. doi: 10.1016/j.critrevonc.2015.02.013. Epub 2015 Mar 11.
Chronic lymphocytic leukemia (CLL) is a disease of the lymphoid system, in which the most common therapy is fludarabine plus cyclophosphamide (FC). The addition of rituximab to FC has been used, a combination known as FCR.
To perform a systematic review with meta-analysis of clinical trials between 2000 and 2012 comparing FC and FCR in patients with CLL.
Electronic databases were searched using keywords related to the objectives of this review. The outcomes examined were progression-free survival and complete remission.
The progression-free survival and the overall survival showed significant difference between the two regimens, with complete remission being more frequent in FCR-treated patients (odds ratio=2.58; 95% CI: 2.13-3.13). Patients treated with FCR showed significantly higher neutropenia and serious adverse reactions.
Despite the favorable results of the FCR regimen on outcomes including complete remission, progression-free survival, and overall survival, there is a lack of methodological rigor and appropriate analyses in many of these studies, and thus, there is a need for further studies examining the effect of rituximab in CLL patients.
慢性淋巴细胞白血病（CLL）是一种淋巴系统疾病，最常见的治疗方法是氟达拉滨加环磷酰胺（FC）。已经使用了利妥昔单抗联合 FC 的方法，这种联合疗法被称为 FCR。
对 2000 年至 2012 年期间比较 CLL 患者中 FC 和 FCR 的临床试验进行系统评价和荟萃分析。
使用与本次综述目的相关的关键词搜索电子数据库。评估的结局是无进展生存期和完全缓解。
两种方案之间的无进展生存期和总生存期有显著差异，FCR 治疗组完全缓解的频率更高（比值比=2.58；95%CI：2.13-3.13）。FCR 治疗组患者中性粒细胞减少和严重不良反应发生率显著升高。
尽管 FCR 方案在包括完全缓解、无进展生存期和总生存期在内的结局方面具有良好的效果，但这些研究中的许多研究缺乏方法学严谨性和适当的分析，因此需要进一步研究利妥昔单抗在 CLL 患者中的作用。
